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Objective: This study aims to identify factors associated with poor adherence to COPD 
treatment in patients receiving a fixed-dose combination (FDC) of inhaled corticosteroids and 
long-acting β
2
-agonist (ICS/LABA), focusing on the importance of inhaler devices.
Methods: We conducted a retrospective and multicenter study based on a review of medical 
registries between 2007 and 2012 of COPD patients (n=1,263) treated with ICS/LABA FDC, 
whose medical devices were either dry powder inhalers (DPIs) or pressurized metered-dose 
inhalers (pMDI). Medication adherence included persistence outcomes through 18 months and 
medication possession ratios. Data on exacerbations, comorbidities, demographic characteristics, 
and health care resource utilization were also included as confounders of adherence.
Results: The analyses revealed that COPD patients whose medication was delivered through 
a DPI were less likely to have medication adherence compared to patients with pMDI, after 
adjusting for confounding factors, especially active ingredients. Younger groups of patients 
were less likely to be adherent compared to the oldest group. Smoker men were less likely to 
be adherent compared to women and non-smokers. Comorbidities decreased the probability of 
treatment adherence. Those patients that visited their doctor once a month were more likely to 
adhere to their medication regimen; however, suboptimal adherence was more likely to occur 
among those patients who visited more than three times per month their doctor. We also found 
that worsening of COPD is negatively associated with adherence.
Conclusion: According to this study, inhaler devices influence patients’ adherence to long-
term COPD medication. We also found that DPIs delivering ICS/LABA FDC had a negative 
impact on adherence. Patients’ clinic and socioeconomic characteristics were associated with 
adherence.
Keywords: adherence, inhaler technique, medication possession ratio (MPR), dry powder 
inhalers (DPIs), pressurized metered-dose inhalers (pMDIs), persistence
Introduction
COPD causes specific inflammatory cell types and structural changes in the airways 
that determine the severity of this condition. In Spain, chronic lung diseases were the 
fourth leading cause of mortality in 2008.1 Furthermore, recent studies have reported 
that ~10.2% of Spanish population between 40 and 80 years have COPD,2 but its 
under-diagnosis is frequent, and it is estimated that 73% of COPD cases have not been 
diagnosed.3 These characteristics make COPD already a very costly condition, which 
is estimated to be equivalent to 0.2% of Spanish gross domestic product.2
Pharmacological treatment should adjust to each patient, guided by severity of 
symptoms, risk of exacerbations, and patient’s response. Maintenance treatment 
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of COPD relies on inhaled agents to control symptoms 
and/or complications of the disease and to prevent exac-
erbations.1 Although these effects are required, inhaled 
pharmacological treatment depends on the efficacy of 
inhaler devices, patient’s ability, and precision for using 
it;4,5 the reliability of devices for delivering the medicine 
directly to patients’ lungs;6,7 and patient’s compromise 
to comply timing, dosage, and frequency of medication 
taking.8,9 Suboptimal adherence within chronic conditions 
has been largely documented.10,11 Specifically, the lack of 
adherence toward medication regime can cause progression 
of COPD, more severity of symptoms and exacerbations, 
hospitalization, and detriment of the quality of life among 
COPD patients.12–14 Medication adherence is a complex 
issue that can be defined as the degree to which a patient’s 
medication-taking behavior and/or executing lifestyle 
changes correspond with agreed recommendations from 
a health care professional with respect to timing, dosage, 
and frequency.8,11 Over the last few years, researchers from 
several disciplines raised that adherence is an important 
problem given that is influenced not only by the increas-
ingly complexity of lifelong therapy regimens but also 
by multiple clinical and nonclinical factors, to which we 
have to add the sociodemographic changes of a population 
aging.15 These aspects represent a challenge for national 
health care systems worldwide that should be analyzed 
from a multidisciplinary perspective.4,6,13,14
Although inhaled corticosteroids and long-acting 
β
2
-agonist (ICS/LABA) fixed-dose combinations (FDCs) 
have shown to relieve COPD symptoms similarly, recent 
research has shown that inhaler technique might affect adher-
ence and hence efficacy of pharmacological treatment.2–4 
Inhaler technique is different between dry powder inhalers 
(DPIs) and pressurized metered-dose inhalers (pMDIs). Each 
of the devices is associated with procedure, which is also 
affected by the ability of patients to handle it. The aim of 
this study was to examine medication adherence in COPD 
patients, focusing on the associations between adherence 
with COPD medication and inhaler devices, such as DPI and 
pMDI, while adjusting for the potential effect of the active 
ingredients. Moreover, some other factors that could be affect-
ing medication adherence, such as clinical or socioeconomic 
characteristics of patients, were also analyzed.
Materials and methods
study sample
We conducted a retrospective and multicenter study based on 
a review of medical registries of COPD patients treated with 
ICS/LABA FDC, whose inhaler devices were either DPIs or 
pMDIs. Diagnosis was spirometry based, which was useful 
to classify patients into three categories: mild, moderate, and 
severe. Criteria were always the doctor’s opinion. The study 
population included patients attending primary care centers, 
whose population was mostly urban, with a low-to-medium 
socioeconomic level.
The study sample comprised all COPD patients, who 
initiated their treatment with ICS/LABA FDC between 
January 1, 2007 and June 30, 2014. Moreover, patients 
fulfilled the following characteristics: 1) aged $35, 2) 
time of diagnosis .3 years, and 3) were required to have 
registries with regular monitoring for 18 months (ie, those 
who were part of the long-term prescription program to 
obtain prescriptions with a confirmed record of the daily 
dosage, time interval, and duration of each treatment) 
(n=1,645). We excluded patients who were transferred 
outside the area, patients permanently institutionalized, 
patients who died during the period of analysis (n=382), 
and patients who presented clinical history of pulmonary 
emphysema, bronchiectasis, cystic fibrosis, and bronchial 
neoplasia.
Data source and variables
This retrospective study used integrated medical and phar-
macy claims’ data to identify the impact of inhaler technique 
toward adherence outcomes. Database contains informa-
tion on COPD treatments with ICS/LABA FDC according 
to the Anatomical Therapeutic Chemical Classification 
System. We linked each treatment to its inhaler device, 
which could be a DPI or a pMDI. Thus, within DPIs were 
included Turbuhaler®, Accuhaler®, and NEXThaler® that 
delivered formoterol/budesonide, salmeterol/fluticasone, and 
formoterol/beclomethasone, respectively. pMDIs delivered 
either formoterol/beclomethasone or salmeterol/fluticasone. 
Database is managed by Badalona Serveis Assitencials, 
which provides services to ten primary care centers, one 
hospital, and one sociohealth center. Ethics approval for 
the database to be used for research was granted by the 
Ethics Committee of the Hospital Universitari Germans 
Trías i Pujol.
Information on persistence was obtained for 1 year and 
half, indicating whether patient kept taking that treatment 
(persistence) at the third, sixth, 12th, and 18th months 
(Figures 1 and 2). Information on medication possession 
was also obtained by patient’s refill count as well as data 
on duration by the number of days patient should be con-
suming the medication. Demographic characteristics of 
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this sample were age, sex, and whether the patient was 
retired or not.
Furthermore, we gathered data of other potential con-
founders of medication adherence. A number of mild/ 
moderate exacerbations and acute events, defined by the 
GesEPOC recommendations,2 were collected. Medica-
tions, such as oral corticosteroids, systemic antibiotics, 
short-acting β
2
-agonist, short-acting anticholinergic, and 
systemic β
2
-agonists, to treat the symptoms and complica-
tions of COPD were available. Clinical data on comorbidi-
ties were included. Basically, it was indicated whether the 
patients suffered from simultaneous conditions, such as 
hypertension, diabetes, dyslipidemia, arthritis, osteoarthritis, 
depression, and dementia. Also severe events, including 
failures, ischemic heart disease, cerebrovascular diseases, 
and neoplasm, were indicated. Behavior attitudes that could 
derive to higher risk of developing a disease, for instance, 
obesity, smoking habit, and alcoholism, were also included 
as comorbidities. We had also access to number of visits to 
Figure 1 Percentage of persistent patients at the third, sixth, 12th, and 18th months.
Abbreviations: pMDI, pressurized metered-dose inhaler; DPI, dry powder inhaler.
Figure 2 Medication persistence.
Abbreviations: pMDI, pressurized metered-dose inhaler; DPI, dry powder inhaler.





the physician during the period of study. Pharmacy adminis-
trative database also stores gross amount of pharmaceutical 
expenditure per patient. Data were adapted into our model by 
obtaining patient’s average cost per month because Spanish 
patients have low co-payment levels for their medication; 
we approximated the potential cost that patients could face 
each month.
Calculation of patient’s medication 
adherence
To calculate adherence, we utilized the medication possession 
ratio (MPR), which is calculated by dividing the number of 
days supplied for a given medication by the number of days in 
the study, and persistence data.16 Persistence is defined as the 
duration of time from initiation to discontinuation of therapy. 
Clinical outcomes are affected not only by how well patients 
take their medication but also by how long they take them, so 
the effect on how well patients take ICS/LABA FDC can be 
observed without being disturbed by discontinuation. First, 
we identified patients who last 18 months with their medica-
tion, which implied that they were persistent. These patients 
were analyzed to obtain adherence by using the MPR. There-
fore, within these persistent patients, we applied a cut-point 
of 90% to the MPR. Since MPR tends to be overestimated,9,17 
we also increased the limit to consider medication adherence. 
We had an ordered categorical variable, which showed to be 
very useful to identify persistence and adherence patterns: 
patients first need to be persistent with their treatment, and 
then they need to comply with their prescriptions.4,9 This 
variable reflects patients who are not neither persistent nor 
adherent, patients who are persistent but nonadherent, and 
patients who are persistent and showed adherence to their 
medication (Figure 3). Finally, to check the robustness of 
our findings, we decided to use the most common cut-point 
that is 80% to the MPR.13,18 This analysis focuses on factors 
that diminish medication adherence.
analysis
To illustrate the distribution of patient’s adherence within 
each medical device (DPI or pMDI), we tabulated sample 
characteristics for patients using either a DPI or a pMDI 
(Table 1). Univariate associations between medication 
adherence, medical device, and several confounders, such 
as age, comorbidities, exacerbations, severity of COPD, 
medication to treat COPD, and drug cost, were analyzed 
(Table 2). To perform basic analysis, we only included sta-
tistically significant variables from the univariate analysis 
into the first specification (Table 3).
With reference to health care utilization, visits to physi-
cians were categorized in order to explore the association of 
having, on average, none or one visit per month, between 
one and three visits per month, and more than three visits 
per month (baseline will be none or one visit per month). 
We considered a variable for comorbidity status, which was 
categorized as having one, two, or more than three conditions, 
besides COPD.
Figure 3 Percentage of adherent patients by each inhaler device (n=1,263).
Notes: nonpersistent patient = patient who discontinued their therapy before the 18th month, persistent + nonadherent patient = patient who did not discontinue therapy 
but was ,90% of the MPr, and adherent patient = patient who did not discontinue their therapy but was .90% of the MPr.
Abbreviations: pMDI, pressurized metered-dose inhaler; DPI, dry powder inhaler; MPr, medication possession ratio.
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Moreover, to consider the potential heterogeneity sources 
across age groups, the continuous variable age was split into 
five groups. Utilization of medication to treat COPD, besides 
ICS/LABA FDCs, was combined in a single variable that 
captures number of medication took per patient during the 
period of study. We did not analyze each pattern by itself 
because we are interested on adherence patterns in patients 
attempting to take ICS/LABA FDC chronically. Tables 2–4 
contain results expressed in percentage points (pp) and odd 
ratios.
Table 1 Characteristics of COPD patients according to the type of inhaler device: DPI or pMDI
Characteristics pMDI (n=492) DPI (n=771) Total (n=1,263) P-value
Male (%) 38.95 61.04 83.45 0.735
age, mean (sD) (years) 70.54 (10.37) 70.66 (9.91) 70.61 0.326
39–50 5.28 3.50 4.20 –
51–61 12.40 13.75 13.22 –
62–71 33.54 32.68 33.02 –
72–83 40.04 40.73 40.46 –
84–97 8.74 9.34 9.11 –
retired status (%) 87.2 89.23 88.44 0.966
Time since COPD was diagnosed, mean (sD) (years) 15.0 (5.19) 15.44 (5.04) 15.38 (5.10) 0.994
severity of COPD (%)
Mild 17.89 14.79 15.99 –
Moderate 77.85 80.80 79.65 –
severe 4.27 4.41 4.35 –
FeV1, mean (sD) 76.6 (9.9) 79.1 (9.9) 79.2 (9.9) 0.256
ICs/laBa FDC (%)
Formoterol/beclomethasone 24.59 17.12 20.03 –
Formoterol/budesonide 0.0 51.88 31.67 –
Salmeterol/fluticasone 75.41 31.00 48.30 –
exacerbations (%) (binary on whether patients suffered an 
exacerbation or not)
36.99 42.15 40.14 0.068
Moderate 31.5 36.96 34.84 ,0.001
acute 16.06 14.92 15.36 0.630
Comorbidities (%)
Obesity 38.62 40.86 39.98 0.650
smoking 21.14 19.58 20.19 0.743
alcoholism 6.91 6.10 6.41 0.891
Cerebrovascular disease 34.15 35.80 35.15 0.948
hypertension 59.35 60.57 60.10 0.650
Diabetes 28.66 28.40 28.50 0.732
Dyslipidemia 52.44 49.68 50.75 0.518
Osteoarthritis 8.40 6.28 7.17 0.099
arthritis 20.42 21.16 20.73 0.714
stroke 23.78 25.42 24.78 0.510
Ischemic heart disease 16.06 15.30 15.60 0.948
Failures 25.20 27.11 26.37 0.987
Dementia 6.50 6.87 6.73 0.964
Depression 24.19 26.72 25.73 0.855
neoplasm 16.26 17.12 16.79 0.846
Other medication to treat COPD (%) 84.76 84.95 84.88 –
Oral corticosteroids 8.54 8.17 8.31 0.856
systemic antibiotics 2.7 7.0 5.9 ,0.05
saBa 80.3 80.4 80.3 0.862
short-acting anticholinergic 57.72 55.12 56.14 0.364
number of visits to doctor, mean (sD) 18.99 (13.28) 21.99 (14.24) 20.82 (13.94) ,0.001
average cost per month, mean (sD) (euros) 64.95 (43.54) 62.75 (44.10) 63.60 (43.88) 0.3852
Mean of total health care cost per patient, mean (sD) (euros) 1,920.99 (1,427.22) 2,013 (1,716.5) 1,977 (1,716.5) 0.3527
Note: Patients’ characteristics who visited their primary care center between January 2007 and June 2014.
Abbreviations: DPI, dry powder inhaler; pMDI, pressurized metered-dose inhaler; sD, standard deviation; FeV1, forced expiratory volume in 1 second; ICs/laBa, inhaled 
corticosteroids and long-acting β2-agonist; FDC, fixed-dose combination; COPD, chronic obstructive pulmonary disease; SABA, short-acting β2-agonist.






Clinical and demographic characteristics
Persistence rates were diminishing throughout 18 months 
and were similar among inhaler devices at the 18th month 
(Figures 1 and 2). We could identify the final proportion of 
adherent patients on the basis of methodology described in 
the “Calculation of patient’s medication adherence” section. 
Remarkably higher rates of discontinuation were observed 
in patients using a DPI. However, patients who have medi-
cation adherence were similar in both groups (Figure 3). 
Sociodemographic and clinical characteristics of 1,263 COPD 
patients tabulated by an inhaler device are shown in Table 1. 
A total of 38.95% of patients used a pMDI and 61.05% used 
a DPI during the time of study. The mean age of patients was 
71 years, most of them were retired (88.44%), and 83.45% of 
them were men. Time since diagnosis (in years) was similar in 
both groups. The most frequent comorbidity observed in this 
sample was hypertension (60.1%), followed by dyslipidemia 
(50.75%), which were very similar in both groups. Patients 
with moderate COPD represent 79.65%, and the distribution 
Table 2 Univariate analysis of each potential confounders of adherence
Explanatory variables Category Adherence (n=1,263)
Percentage points Odds ratios 95% CI P-value
Medical device DPI (baseline pMDI) -7.85 0.72 0.583–0.8686 0.002
ICs/laBa FDC (baseline formoterol/beclometasone) Formoterol/budesonide -3.58 0.858 0.640–1.150 0.308
Salmeterol/fluticasone 2.98 1.13 0.860–1.487 0.378
Therapy line (baseline first line) second line 16.55 1.96 1.363–2.814 0.000
Third line 24.75 2.75 1.222–6.186 0.011
age -0.35 0.98 0.975–0.995 0.004
sex (baseline men) 6.29 1.30 0.985–1.715 0.063
retired status -3.14 0.87 0.638–1.204 0.417
Obesity 4.61 1.21 0.985–1.493 0.069
smoking 7.63 1.37 1.066–1.777 0.014
stroke -6.73 0.75 0.594–0.957 0.020
Cerebrovascular disease -6.72 0.75 0.608–0.935 0.010
hypertension 0.89 1.04 0.843–1.278 0.724
Diabetes -1.80 0.93 0.738–1.164 0.517
Dislipemia -1.89 0.92 0.753–1.133 0.448
Osteoarthritis 0.87 1.03 0.808–1.330 0.775
arthritis -0.31 0.98 0.654–1.489 0.951
alcoholism 6.51 1.31 0.863–1.993 0.203
Ischemic cardiomyopathy -0.83 0.96 0.730–1.277 0.807
Failures 2.89 1.12 0.895–1.421 0.306
Dementia -9.18 0.68 0.446–1.309 0.075
Depression -2.07 0.92 0.727–1.156 0.465
neoplasm 3.93 1.17 0.896–1.548 0.239
number of exacerbations 4.48 1.21 1.114–1.311 0.000
number of severe exacerbations -9.41 0.91 0.684–1.210 0.518
number of mild/moderate exacerbations 5.77 1.28 1.165–1.403 0.000
severity of COPD (baseline mild) Moderate 4.80 1.23 0.930–1.619 0.148
severe 22.15 2.47 1.374–4.459 0.003
Time since COPD was diagnosed -1.72 0.93 0.909–0.947 0.000
Other medication to treat COPD 5.66 1.27 1.181–1.375 0.000
Oral corticosteroids 11.32 1.61 1.307–1.990 0.000
systemic antibiotics 14.83 1.87 1.444–2.430 0.000
saBa 16.95 2.06 1.629–2.604 0.000
short acting 
anticholinergic
7.83 1.388 1.130–1.707 0.002
β2 agonists (systemic) 6.82 1.33 0.903–1.956 0.149
long acting anticholinergic agents 13.56 1.77 1.393–2.260 0.000
Cost -0.25 0.98 0.986–0.991 0.000
Visits to doctor 0.41 1.017 1.009–1.25 0.000
Abbreviations: CI, confidence interval; DPI, dry powder inhaler; pMDI, pressurized metered-dose inhaler; ICS/LABA, inhaled corticosteroids and long-acting β2-agonist; 
FDC, fixed-dose combination; COPD, chronic obstructive pulmonary disease; SABA, short-acting β2-agonist.
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of disease severity is very similar across clusters. It is worth 
mentioning that the use of ICS/LABA FCD in COPD sub-
jects is limited to severe or moderate-to-severe obstruction 
and common exacerbations; however, we observed patients 
classified as mild who use these therapies. Furthermore, one 
DPI included does not have indication for COPD in Spain 
but our sample shows that currently is being used with such 
a propose, which might be explained by a certain freedom 
to prescribe off-label. Almost half of the patients (40.79%) 
experienced at least one exacerbation.
Table 2 contains results of univariate regressions. DPI 
utilization was negatively correlated with adherence; on the 
contrary, the effect of active ingredients was not statistically 
significant. Clinical characteristics, such as COPD severity, 
time since diagnosis, number of mild and moderate exac-
erbations, and some comorbidities, such as smoking and 
cerebrovascular diseases, were negatively correlated with 
adherence, except for moderate exacerbations that were 
positively correlated with it. None of the diseases that are 
mobility limiting were significant. Long-acting anticholin-
ergic agents were positively correlated with adherence as 
well as most of the medication to treat COPD, except for 
systemic administration of β
2
-adrenoceptor agonists that 
were not statically significant. Pharmaceutical costs were 
negatively correlated with adherence, and visits to physician 
were positively correlated with it.
Inhaler technique and other confounders 
affecting patient’s adherence to the 
COPD treatment
Results are shown in Table 3 with and without active ingre-
dient variable. Remarkably, variable for inhaler devices 
increased its significance (P,0.001), and the probability of 
adherence by a patient using a DPI would be diminished by 
almost 10 pp compared to that of a patient using pressurized 
inhalers. These measures were adjusted for confounders, 
and some of them were significant. For instance, time since 
diagnosis is negatively associated with medication adher-
ence. In case of moderate exacerbations, the link is positive. 
Regarding health care resources, the coefficient of pharma-
ceutical cost would have a small negative impact on medica-
tion adherence, while the effect of doctor’s visit is positive.
In Table 4, we present the results of the regression that 
provided the adjusted measures of association between the 




Without active ingredients Controlling for active ingredients
Percentage points Odd ratios 95% CI Percentage points Odd ratios 95% CI
Medical device DPI (baseline pMDI) -9.95* 0.60* 0.481–0.750 -9.57* 0.61* 0.467–0.802
ICs/laBa FDC (baseline formoterol/beclometasone)
Formoterol/budesonide - – – 2.07 1.11 0.798–1.556
Salmeterol/fluticasone - – – 3.37 1.19 0.893–1.586
severity of COPD (baseline mild)
Persistent moderate 11.22* 1.91** 1.323–2.766 11.65* 1.89* 1.311–2.741
Persistent severe 7.08 1.49 0.645–3.484 6.74 1.47 0.632–3.426
Time since COPD was diagnosed -1.15* 0.942 0.917–0.968 -1.14* 0.94* 0.918–0.968
Therapy line
second 10.13** 1.637** 1.125–2.380 10.21** 1.64** 1.130 – 2.390
Third 20.45** 2.624** 1.077–6.361 20.14** 2.58* 1.063–6.305
age -0.11 0.994 0.979–1.009 -0.12 0.99 0.978–1.009
sex 4.02 1.23 0.161–0.921 0.41 1.23 0.923–1.644
Obesity 2.12 1.11 0.894–1.391 1.94 1.10 0.885–1.379
smoking 4.63 1.268 0.958–1.677 4.50 1.260 0.952–1.667
stroke -3.34 0.842 0.588–1.206 -3.21 0.848 0.592–1.214
Cerebrovascular disease -3.84 0.821 0.551–1.222 -3.85 0.821 0.551–1.222
exacerbations -6.20** 0.72** 0.529–1.001 -6.57** 0.714** 0.517–0.984
Mild/moderate exacerbations 10.22** 1.69** 1.188–2.400 10.62** 1.72** 1.210–2.457
long-acting anticholinergic agent 2.77 1.15 0.838–1.584 2.73 1.150 0.836–1.582
Pharmacological cost -0.21* 0.989* 0.986–0.992 -0.21** 0.989** 0.986–0.992
Visits to doctor 0.24** 1.012** 1.004–1.021 0.24** 1.012** 1.004–1.021
Notes: *P,0.001 and **P,0.05.
Abbreviations: CI, confidence interval; DPI, dry powder inhaler; pMDI, pressurized metered-dose inhaler; ICS/LABA, inhaled corticosteroids and long-acting β2-agonist; 
FDC, fixed-dose combination; COPD, chronic obstructive pulmonary disease.





inhaler technique and medication adherence and showed to fit 
the data better than previous models. This analysis revealed 
that patients treated with ICS/LABA FDC delivered by a DPI 
were less likely to adhere to their COPD treatment compared 
to patients that used a pMDI. By contrast, the variable that 
captures the association between ICS/LABA and adherence 
was not significant. Regarding disease severity, worsening 
of COPD is not negatively associated with adherence. This 
effect is not consistent with the coefficient of time since the 
diagnosis, which implies that the probability of medica-
tion adherence would decrease by 0.7 pp, for an extra year 
with COPD.
Table 4 Final specification: results of multivariable analysis examining the associations between inhaler devices for ICS/LABA FDC and 
adherence
Explanatory variables (McFadden’s R2=0.2898) Adherence (n=1,263)
Percentage points Odds ratio 95% CI
Medical device DPI (baseline pMDI) -5.38* 0.71* 0.521–0.970
ICs/laBa FDC (baseline formoterol/beclomethasone)
Formoterol/budesonide -0.38 0.97 0.661–1.440
Salmeterol/fluticasone 3.07 0.72 0.241–2.174
severity of COPD (baseline moderate)
Mild -9.81* 0.53* 0.300–0.960
severe -5.15 0.72 0.241–2.174
Time since COPD was diagnosed -0.78* 0.95* 0.923–0.981
Therapy line (baseline first line)
second line -1.27 0.92 0.603–1.413
Third line 1.69 1.11 0.437–2.823
sex (baseline men) 3.01 1.21 0.816–1.782
age (as a continuous variable) -1.23** 0.96** 0.887–0.966
age groups (baseline 87–97)
39–51 -34.04** 0.99* 0.169–0.578
51–61 -29.69** 0.13* 0.036–0.501
61–71 -23.04** 0.212* 0.081–0.552
72–83 -16.62** 0.32** 0.173–0.599
retired status 5.05 1.37 0.736–2.563
number of comorbidities
2 -0.74 0.95 0.662–1.374
3 -10.96* 0.49* 0.282–0.864
Obesity 6.26 1.47 0.975–2.231
smoking 14.52* 2.248* 1.105–5.587
smoking men -28.73** 0.167** 0.034–0.800
hypertension 6.29* 1.48* 1.085–2.018
Diabetes 5.00 1.36 0.981–1.902
acute exacerbation -8.36* 0.59* 0.378–0.933
Moderate exacerbation 2.20 1.14 0.914–1.438
long-acting anticholinergic agents 5.23 1.37 0.928–2.050
Other medication to treat COPD 2.44 1.16 0.995–1.362
additional visit to the doctor 2.15** 1.14** 1.122–1.165
Visits to doctor
Two times per month (on average) -33.88** 0.11** 0.797–0.165
Three times per month (on average) -67.25** 0.0028** 0.009–0.007
average pharmacological cost per month 0.04 1.00 0.999–1.006
Notes: *P,0.05 and **P,0.001.
Abbreviations: ICs/laBa, inhaled corticosteroids and long-acting β2-agonist; FDC, fixed-dose combination; CI, confidence interval; DPI, dry powder inhaler; pMDI, 
pressurized metered-dose inhaler; COPD, chronic obstructive pulmonary disease.
The categorical variable for the number of comorbidities 
shows that having more than three multiple conditions would 
impact negatively on medication adherence, despite most 
of the comorbidities in the previous regressions were not 
statistically significant. Regarding comorbidities, we found 
that hypertension was positively correlated with adherence 
as well as smoking. Regarding patients’ characteristics, age 
appeared to be determinant, affecting adherence to treatment 
negatively. However, this effect becomes smaller as we 
moved to older age groups.
An additional acute exacerbation for COPD patients 
was negatively associated with medication adherence, but 
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number of medication to treat COPD, besides ICS/LABA 
FDC, showed to be not significant. An additional visit to 
the doctor was positively associated with medication adher-
ence. Conversely, more than one physician visit per month 
is negatively associated with adherence. Some other poten-
tial confounders, such as sex, concomitant medication, and 
moderate exacerbations, were not statistically significant for 
explaining adherence with COPD medication. Additionally, 
results of the interaction term of sex and smoking suggest 
that the probability of medication adherence was reduced 
for smoking men compared to smoking women and non-
smokers. Regarding health care resources, cost was not 
significant. Robustness check confirmed our results, and the 
effect of inhaler technique increases its significance toward 
suboptimal adherence (P,0.001).
Discussion
These analyses revealed that after adjustment for confound-
ing variables, especially the active agents, patients treated 
with ICS/LABA FCD delivered using a DPI (Accuhaler®, 
NEXThaler®, and Turbuhaler®) were less likely to show 
adherence compared to patients treated with ICS/LABA 
FCD delivered using a pMDI. Results are striking because, 
despite the inclusion of several confounders of adherence, 
there was still a statistically significant coefficient of the vari-
able of inhaler devices’ utilization, suggesting that factors 
related only to inhaler devices might weaken probability of 
medication adherence. We can find critical errors of DPIs in 
the literature. The most frequently reported flaw is failure to 
exhale before inhaling and in consequence, failure to use a 
forceful and deep inhalation.19 Moreover, DPIs included in 
our analysis present errors regarding the metering of the dose 
and positioning the inhaler.19 Suboptimal adherence limits 
the efficacy of inhalation therapy, since there are negative 
impacts in outcomes as survival and cost as well as clinical 
outcomes.20,21 Although there is not an agreement on the situ-
ation that predisposes to inhaler misuse, the identification of 
associations between inhaler technique and patients’ adher-
ence shed some light on reasons why suboptimal adherence 
has become a major problem.3,18,22,23
Our results are consistent with the previous analyses that 
described several factors affecting medication adherence 
negatively.8,24,25 In our analysis, we identified factors that 
affect adherence of long-term inhalation therapy in COPD 
patients. Age was negatively associated with adherence.26 
This effect is consistent with time since diagnosis, which indi-
cates a negative in adherence as time passes toward adher-
ence to long-term therapy. However, the effect decreases 
along with age.27,28 Hypertension patients were more likely 
to medication adherence, which is plausible because these 
patients might be also more controlled due to high blood 
pressure, and adherence in hypertension is higher compared 
to COPD, which could also influence adherence for COPD.29 
Conversely, arthritis and osteoarthritis have not shown to 
be statistically significant, although these conditions con-
tribute to an inability of device utilization.30 These results 
are likely to be explained by the constrained subsample size 
of these comorbidities; hence, further research is needed in 
this area.
Some patients failed to comply with physician’s recom-
mendations since they did not quit smoking (19% of the 
sample). Smoking cessation is the most effective way of 
slowing the progression of this disease.12 Therefore, it is 
plausible to think that patients are also nonadherent to their 
medication.31 Indeed, our results suggest that the smoking 
men’s probability of medication adherence decreased by 
30 pp. Although sex was not crucial for explaining adher-
ence, the negative effect of the interaction term between 
smoking status and men is considerable. The sample was 
mostly composed of men, who represent the common COPD 
patient.2 However, this pattern is changing since incidence 
of smoking, main cause of COPD, has increased in women, 
which have now greater health risks.2
Regarding health care utilization, we identified two 
effects of visiting the doctor. The effect of doctor visit 
would increase the probability of medication adherence.18 
Conversely, patients who have visited their doctor more than 
three times per month were more likely to have suboptimal 
adherence. Results are feasible since health care professional 
interventions are consistently positive for adherence and 
compliance.32 However, many visits to the doctor negatively 
associated might indicate serious problems and patients are 
pushed to visit several times their physician.14,15,33 Cost was 
not finally statistically significant toward adherence. This 
is plausible since Spanish patients do not bear 100% of the 
pharmaceutical costs directly.34
These results should be interpreted within the context of 
study limitations. First, this is a retrospective study, which is 
vulnerable to bias. For instance, we could identify endogene-
ity in results for exacerbations, since it is likely that the causal 
direction goes from medication adherence toward exacerba-
tions and not vice versa.13,35 Second, this study was conducted 
in a single health system; thus, results may not be extrapolate 
to other populations. However, trends are similar to previous 
research.17,20,23 Third, the assumption that obtaining prescrip-
tion was equivalent to taking the medication, which might 
not be completely true. Moreover, our study approach to 
quantify adherence was done by using the MPR, which has 





been reported to be biased upward by previous research.9,14 
Nevertheless, we tried to correct this by elevating the cut-
point, so fewer patients would be seen as adherent, and testing 
robustness of estimates due to this cut-point confirmed our 
findings. Actually since we obtain the persistence to COPD 
long-term medication, our estimates could be more accurate 
than those of few others who also used MPR without taking 
into account persistence. It is also true that tracking adherence 
patterns may imply to have data across time, which can be 
accomplished by analyzing adherence prospectively as well 
as analyzing other issues related with poor adherence that 
were not measured, such as intentional and nonintentional 
nonadherences, patients’ preferences, and specific steps that 
the patients fail to complete within the process of taking their 
medicine.5,36,37 The fact that NEXThaler® was introduced in 
2012 could limit our study, but dataset provides a sufficient 
number of cases using NEXThaler® in order to be included 
within the DPI group. Finally, we could not obtain some 
patients’ characteristics, such as race, level of education, 
type of job, and few others. This problem of data limitation 
also restricts our outcomes.
Conclusion
Medication adherence in COPD is crucial for optimizing 
clinical outcomes, and there are several factors that condi-
tion it. Inhaler devices are expected to help optimization of 
active ingredients. However, we found that DPIs included 
in our analysis (Turbuhaler®, Accuhaler®, and NEXThaler®) 
delivering ICS/LABA FDCs had a negative effect on 
patients’ medication adherence compared to pMDIs. The 
findings reviewed here suggest that the pharmacological 
effectiveness of the FDC, which seemed to be very promis-
ing in the beginning, might be conditioned by the inhaler 
technique associated with inhaler devices. The special feature 
of our findings is that we adjusted for the effects of the active 
ingredients in order to explore the specific effect of inhaler 
technique toward adherence. We have also corroborated that 
patients’ clinic and demographic characteristics are associ-
ated with adherence.
Suboptimal adherence is a major problem in long-term 
therapies, such as COPD treatment. The consideration of 
incidence trends and risk factors related to COPD, in addition 
to the aging of population, makes very relevant to overcome 
barriers to treatment adherence in order to avoid progression 
of the disease and waste of resources because patients can-
not obtain the maximum efficacy of their treatment, even 
among those who want to take their medicine correctly. 
Overcoming barriers passes through the innovation of inhaler 
devices. Instead of attributing all the responsibility of poor 
utilization due to human errors, more intuitive and simple 
designs are needed.
Acknowledgments
BCN Health Economics and Outcomes Research S.L., pro-
vided statistical analysis and editorial support.
Disclosure
This study was sponsored by Teva Pharmaceutical S.L.U. 
JD is employed by the University of Barcelona. GR is an 
employee of BCN Health Economics and Outcomes Research 
S.L., Barcelona, Spain, an independent contract health eco-
nomic organization that has received research funding from 
TEVA Pharmaceutical S.L.U. AS is employed by Badalona 
Serveis Assistencials S.A. PF and RS are employed by TEVA 
Pharmaceutical Industries Ltd and they work in the Medical 
Department. ST is also employed by TEVA Pharmaceuti-
cal Industries Ltd. The authors report no other conflicts of 
interest in this work.
References
1. Grupo de trabajo de la Guía de Práctica Clínica para el Tratamiento 
del Pacientes con Enfermedad Pulmonar Obstructiva Crónica (EPOC) 
[Working Group of the Clinical Practice Guideline for the Treatment of 
Patients with Chronic Obstructive Pulmonary Disease (COPD)]. Plan de 
Calidad para el Sistema Nacional de Salud del Ministerio de Sanidad, 
Servicios Sociales e Igualdad. Unidad de Evaluación de Tecnologías 
Sanitarias de la Agencia Laín Entralgo [Quality Plan for the National 
Health System of the Ministry of Health, Social Services and Equality. 
Unit Health Technology Assessment of the Lain Entralgo Agency]; 2001. 
Guías de Práctica Clínica en el SNS: UETS n 2011/6.
2. Miravitlles M, Soler-Cataluña JJ, Calle M, et al. Spanish guideline for 
COPD (GesEPOC). Update 2014. Arch Bronconeumol. 2014;50(suppl 1): 
1–16.
3. Ancochea J, Miravitlles M, García-Río F, et al. Infradiagnóstico de 
la enfermedad obstructiva crónica en mujeres: cuantificación del 
problema, determinantes y propuestas de acción [Underdiagnosis of 
chronic obstructive pulmonary disease in women: quantificacion of 
the problem, determinants and proposed actions]. Arch Bronconeumol. 
2013;49(6):223–229.
4. Inhaler Error Steering Committee, Price D, Bosnic-Anticevich S, et al. 
Inhaler competence in asthma: common errors, barriers to use and recom-
mended solutions. Respir Med. 2013;107(1):37–46.
5. Melani AS, Bonavia M, Cilenti V, et al; Gruppo Educazionale Associ-
azione Italiana Pneumologi Ospedalieri. Inhaler mishandling remains 
common in real life and is associated with reduced disease control. Respir 
Med. 2011;105:930–938.
6. Lavorini F, Fontana GA, Usmani OS. New inhaler devices – the good, 
the bad and the ugly. Respiration. 2014;88:3–15.
7. Roy A, Battle K, Lurslurchachai L, Halm EA, Wisnivesky JP. Inhaler 
device, administration technique and adherence to inhaled corticosteroids 
in patients with asthma. Prim Care Respir J. 2011;20(2):148–154.
8. Cramer JA, Roy A, Burrell A, et al. Medication adherence and persis-
tence: terminology and definitions. Value Health. 2008;11(1): 44–47.
9. Christensen AJ. Patient Adherence to Medical Treatment Regimens: 
Bridging the Gap Between Behavioral Science and Biomedicine. New 
Haven, CT: Yale University Press; 2004.
International Journal of COPD
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journal
The International Journal of COPD is an international, peer-reviewed 
journal of therapeutics and pharmacology focusing on concise rapid 
reporting of clinical studies and reviews in COPD. Special focus is given 
to the pathophysiological processes underlying the disease, intervention 
programs, patient focused education, and self management protocols. 
This journal is indexed on PubMed Central, MedLine and CAS. The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.





The importance of inhalation devices in adherence outcomes
 10. Rolnik S, Pawloski PA, Hedblom BD, Asche SE, Bruzek RJ. Patient 
characteristics associated with medication adherence. Clin Med Res. 2013; 
11(2):54–65.
 11. World Health Organization (WHO). Adherence to Long-Term Thera-
pies: Evidence for Action. Geneva, Switzerland; 2003. Available from: 
http://www.who.int/chp/knowledge/publications/adherence_report/en/. 
Accessed December, 2014.
 12. From The Global Strategy for the Diagnosis, Management and Preven-
tion of COPD, Global Initiative for Chronic Obstructive Lung Disease 
(GOLD); 2015. Available from: http://www.goldcopd.org/. Accessed 
March, 2015.
 13. Williams LK, Pladevall M, Xi H, et al. Relationship between adherence 
to inhaled corticosteroids and poor outcomes among adults with asthma. 
J Allergy Clin Immunol. 2004;114(6):1288–1293.
 14. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations 
between dose regimens and medication adherence. Clin Ther. 2001; 
23(8):1296–1310.
 15. Barnestein-Fonseca P, Leiva-Fernández J, Vidal-España F, García-Ruíz A, 
Prados-Torres D, Leiva-Fernández F. Is it possible to diagnose the 
therapeutic adherence of patients with COPD in clinical practise? 
A cohort study. BMC Pulm Med. 2011;11:6.
 16. Stern L, Berman J, Lumry W, et al. Medication adherence and disease 
exacerbation in patients with asthma: a retrospective study of managed 
care data. Ann Allergy Asthma Immunol. 2006;97(3):402–408.
 17. Steiner JF, Prochazka AV. The assessment of refill adherence using 
pharmacy records: methods, validity and applications. J Clin Epidemiol. 
1997;50(1):105–115.
 18. Hughes D, Cowell W, Koncz T, Cramer J; International Society for 
Pharmacoeconomics and Outcomes Research Economics of Medication 
Adherence Working Group. Methods for integrating medication adher-
ence and persistence in pharmacoeconomic evaluations. Value Health. 
2007;10(6):498–509.
 19. Lavorini F, Magnan A, Dubus JC, et al. Effect of incorrect use of dry 
inhalers on management of patients with asthma and COPD. Respir 
Med. 2008;102(4):593–604.
 20. Bryant J, McDonald VM, Boyes A, Sanson-Fisher R, Paul C, Melville J. 
Improving medication adherence in chronic obstructive pulmonary 
disease: a systematic review. Respir Res. 2013;14:109.
 21. Pedersen S, Frost L, Arnfred T. Errors in inhalation technique and 
efficiency of inhaler use in asthmatic children. Allergy. 1986;41: 
118–124.
 22. Khassawneh BY, Al-Ali MK, Alzoubi KH, et al. Handling of inhaler 
devices in actual pulmonary practice: metered-dose inhaler versus dry 
powder inhalers. Respir Care. 2008;53(3):324–328.
 23. Molimard M, Raherison C, Lignot S, Depont F, Abouelfath A, Moore 
N. Assessment of handling of inhaler devices in real life: an observa-
tional study in 3811 patients in primary care. J Aerosol Med. 2003; 
16(3):249–254.
 24. Crompton GK, Barnes PJ, Broeders M, et al; Aerosol Drug Manage-
ment Improvement Team. The need to improve inhalation technique 
in Europe: a report from the Aerosol Drug Management Improvement 
Team. Repir Med. 2006;100(9):1479–1494.
 25. Epstein S, Maidenberg A, Hallet D, Khan K, Chapman KR. Patient 
handling of a dry-powder inhaler in clinical practice. Chest. 2001;120: 
1480–1484.
 26. Gellad WF, Grenard JL, Marcum ZA. A systematic review of barriers to 
medication adherence in the elderly: looking beyond cost and regimen 
complexity. Am J Geriatr Pharmacother. 2011;9(1):11–23.
 27. Billups SJ, Malone DC, Carter BL. The relationship between drug 
therapy nonadherence and patient characteristics, health-related quality 
of life, and healthcare cost. Pharmacotherapy. 2000;20:941–949.
 28. Turner J, Wright E, Mendella L. Predictors of patient adherence to 
long-term home nebulized therapy for COPD. The IPPB study group. 
Intermittent positive pressure breathing. Chest. 1995;108:394–400.
 29. Cramer JA, Benedict A, Muszbek N, Keskihaslan A, Khan ZM. The 
significance of adherence and persistence in the treatment of diabetes, 
hypertension and dyslipidaemia: a review. Int J Clin Pract. 2008;62(1): 
76–87.
 30. Taffet GE, Donohue JF, Altman PR. Considerations for managing 
chronic obstructive pulmonary disease in the elderly. Clin Interv Aging. 
2014;9:23–30.
 31. Krigsman K, Nilsson JL, Ring L. Adherence to multiple drug therapies: 
refill adherence to concomitant use of diabetes and asthma/COPD 
medication. Pharmacoepidemiol Drug Saf. 2007;16:1120–1128.
 32. Mansur N, Weiss A, Hoffman A, Gruenewald T, Beloosesky Y. Con-
tinuity and adherence to long-term drug treatment by geriatric patients 
after hospital discharge. Drugs Aging. 2008;25(10):861–870.
 33. Dalcin Pde T, Grutcki DM, Laporte PP, et al. Impact of short-term 
educational intervention on adherence to asthma treatment and on 
asthma control. J Bras Pneumol. 2011;37(1):19–27.
 34. Ley 29/2006, de 26 de Julio, de garantías y uso racional de los medica-
mentos y productos sanitarios. BOE num 178: 28122–28165 [Law 
29/2006 of July 26, on guarantees and rational use of medicines and 
health products. BOE Nº178:28122-28165]. Available from: http://
www.boe.es/buscar/doc.php?id=BOE-A-2006-13554
 35. Garcia-Aymerich J, Farrero E, Félez MA, et al; Estudi del Factors de 
Risc d’Agudització de la MPOC investigators. Risk factors of readmis-
sion to hospital for a COPD exacerbation: a prospective study. Thorax. 
2003;58(2):100–105.
 36. Clifford S, Barber N, Horne R. Understanding different beliefs held by 
adherers, unintentional nonadherers, and intentional nonadherers: appli-
cation of the necessity-concerns framework. J Psychosom Res. 2008; 
64(1):41–46.
 37. Chrystyn H, Small M, Milligan G, Higgins V, Gil EG, Estruch J. Impact 
of patients’ satisfaction with their inhalers on treatment adherence and 
health status in COPD. Respir Med. 2014;108(2):358–365.
